ELMD

ElectromedA

NYSE American / Health Care Equipment & Services

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$48.00

+8.3% vs current

Most likely

Base case

45%

Probability

Target price

$41.00

-7.5% vs current

B-

Bear case

25%

Probability

Target price

$33.00

-25.6% vs current

AI sentiment snapshot

Latest data as of 2026-07-01

AI commentary

Primary evidence is strong for a small-cap medtech name because the May 12, 2026 8-K packaged both the earnings release and investor presentation, and both support a positive operating read. Still, external coverage is thin, recent news volume is light, no useful social dataset was provided, and the packet does not include a robust post-print analyst-revision set. Net: sentiment is favorable but should stay in cautious monitoring mode rather than a high-conviction momentum call.

RankAlpha Sentiment Codex - 2026-07-01

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-31catalystThin-coverage digestion risk after a strong quarterHigh impact

ELMD has low coverage, limited visible analyst-target support, and the June 30, 2026 anchor price of $42.30 already sits above the packet's median target summary of about $40.33, so any sign that Q3 strength was helped by temporary mix, slower prescription conversion, or expense reacceleration could pressure the shares even without a broken long-term story.[#PR-EARNINGS-2026-05-13]

2026-08-26eventQ4/FY2026 print must confirm that Q3 operating leverage is durableHigh impact

The May 12, 2026 earnings release and 8-K showed record Q3 revenue of $18.6M (+18.4%), operating income of $3.8M (+76%), 20.3% operating margin, 14 straight quarters of year-over-year revenue and profit growth, and management confidence tied to 86% covered lives under contract plus completed manufacturing optimization; the next report is the clearest validation point for whether that pace is sustainable.[#PR-EARNINGS-2026-05-13][#SEC-8K-2026-05-12]

2027-06-30catalystBronchiectasis penetration and field-force productivity remain the core long-duration driverHigh impact

The investor presentation frames ELMD around a large underpenetrated bronchiectasis airway-clearance market, while the Q3 release showed annualized homecare revenue per weighted average direct sales representative of $1.168M, above the company target range, with hospital revenue also growing 42.5%; sustained rep productivity and broader clinician adoption are the main path to further upside.[#SEC-8K-2026-05-12][#PR-EARNINGS-2026-05-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-01 • Updated nightlySource: Internal modelMethodology